Seagen shared that the company’s Phase III trial of Adcetris (brentuximab vedotin) demonstrated significant improvements in the overall survival of patients diagnosed with advanced classical Hodgkin lymphoma.
Sanofi still expects the French drugmaker’s COVID-19 vaccine to complete a phase 3 trial in first-quarter 2022 and reported a rise in fourth-quarter 2021 sales and earnings on Feb. 4.
Mersana Therapeutics signed a research and licensing deal with Janssen Biotech to access each other’s proprietary technology in discovering new antibody-drug conjugates (ADCs) for three cancer targets.
The U.S. Centers for Disease Control and Prevention pointed out that people in the United States who have received their booster shots are 97 times less likely to die of COVID-19 than the unvaccinated, and people with full doses but no boosters are 14 times less likely to die of the disease.
South Africa’s Afrigen Biologics used the publicly available sequence of Moderna’s COVID-19 mRNA vaccine to make its own version of the shot, which could be tested in humans before the end of 2022, Afrigen’s top executive said on Feb. 3.
Roche said ongoing trials of the company’s Alzheimer’s disease drug candidate gantenerumab are designed to provide unequivocal results on efficacy as controversy continues in the United States over the benefits of a rival’s approved drug.
Shares of LogicBio Therapeutics fell more than 57 percent on February 2 after the company announced that its gene therapy for pediatric patients with methylmalonic acidemia was placed on clinical hold by the U.S. Food and Drug Administration.
Regeneron Pharmaceuticals and Sanofi’s anti-inflammatory drug Dupixent (dupilumab) has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
While food shortage and malnutrition have been a common scenario throughout human history, the worldwide public health crisis caused by the epidemic of obesity is relatively recent.
With two assets licensed from Takeda, Oak Hill Bio launched with a focus on developing therapeutics for patients and extremely preterm infants who are suffering from rare autoimmune diseases.
